Drug
Selurampanel clinical trials
Also written BGG492.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses selurampanel is read from its arms, and is right about nine times in ten.
Testing it · 9
- Phase II BGG492 Capsule Extension for Partial EpilepsyCompletedPhase 2Novartis PharmaceuticalsNCT01338805Written as BGG492
- Efficacy and Safety of BGG492 in the Treatment of MigraineCompletedPhase 2NovartisNCT00892203Written as BGG492
- Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresCompletedPhase 2NovartisNCT01147003Written as Investigational new drug, company code: BGG492
- Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple SclerosisWithdrawnPhase 2Novartis PharmaceuticalsNCT01649050Written as BGG492
- A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine PreventionWithdrawnPhase 2Novartis PharmaceuticalsNCT01617941Written as BGG492
- Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy SurgeryCompletedPhase 2NovartisNCT00887861Written as Investigational new drug, company code: BGG492
- Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492CompletedPhase 2Novartis PharmaceuticalsNCT02150213Written as BGG492
- Effect of BGG492 on EEG in Patients With Photosensitive EpilepsyCompletedPhase 2Novartis PharmaceuticalsNCT00784212Written as BGG492
- Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset SeizuresWithdrawnPhase 2NovartisNCT01167335Written as BGG492
Codes
What other systems call selurampanel · ClinicalTrials.gg INT000056
- MeSH (NLM) C000591013selurampanelOne source NLM
- UNII (FDA) 7WG1MR7DARSELURAMPANELConfirmed FDA, NLM, Wikidata
- Wikidata Q21098868selurampanelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152327SelurampanelOne source FDA
- DrugBank DB12367One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000591013 | selurampanel | One source NLM |
| UNII (FDA) | 7WG1MR7DAR | SELURAMPANEL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098868 | selurampanel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152327 | Selurampanel | One source FDA |
| DrugBank | DB12367 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.